Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 90 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Brimonidine tartrate Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

NCT00413751
View directory record Official record
Conditions
Healthy
Interventions
Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2006 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety and Efficacy of PDP-716

NCT03450629
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Brimonidine Tartrate Ophthalmic Suspension, Brimonidine Tartrate Ophthalmic Solution
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
2 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04944290
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 6, 2026, 9:48 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

NCT01229410
View directory record Official record
Conditions
Vitrectomy
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

Pupil Dilation for Treatment of IFIS

NCT03760185
View directory record Official record
Conditions
Intraoperative Floppy Iris Syndrome
Interventions
Brimonidine Tartrate
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 6, 2026, 9:48 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

NCT06883123
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Prairie Eye Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

NCT02616250
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 3 Interventional

A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness

NCT06803654
View directory record Official record
Conditions
Ocular Redness
Interventions
BTOS-HA, Lumify®
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
11
States / cities
Glendale, California • Newport Beach, California • Northbrook, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

NCT05135286
View directory record Official record
Conditions
Presbyopia
Interventions
BRIMOCHOL™ PF, Carbachol PF, Vehicle
Drug
Lead sponsor
Visus Therapeutics
Other
Eligibility
45 Years to 80 Years
Enrollment
629 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
42
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 3 Interventional

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00061529
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Brimonidine Tartrate Ophthalmic Solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 6, 2026, 9:48 PM EDT
Completed No phase listed Observational

A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT02348476
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
No Intervention
Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Wheaton, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

NCT05294328
View directory record Official record
Conditions
Presbyopia, Refractive Errors, Eye Diseases
Interventions
Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle Proprietary Ophthalmic Solution
Drug
Lead sponsor
LENZ Therapeutics, Inc
Other
Eligibility
45 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
5
States / cities
Glendale, California • Indianapolis, Indiana • Andover, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 6, 2026, 9:48 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

NCT07209410
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine Tartrate Ophthalmic 0.025%
Drug
Lead sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

Internet Surveys and Their Impact on Adherence for Rosacea

NCT03048058
View directory record Official record
Conditions
Rosacea
Interventions
brimonidine topical gel 0.33% & survey, brimonidine topical gel 0.33% & SOC
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

NCT00652483
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Brimonidine ophthalmic solution 0.1%, Brimonidine ophthalmic solution 0.2%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)

NCT00658619
View directory record Official record
Conditions
Macular Degeneration
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, Sham (no implant)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

NCT00811850
View directory record Official record
Conditions
Glaucoma
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
30 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

NCT02419508
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients

NCT03139708
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Alphagan, Phenylephrine, Tropicamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

NCT00693485
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 6, 2026, 9:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

NCT02975557
View directory record Official record
Conditions
Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions
Brimonidine 0.15%, Brimonidine 0.075%, Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

NCT01959230
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 6, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Lumify™ Eyedrops on Eyelid Position

NCT03782701
View directory record Official record
Conditions
Eyelid Droop
Interventions
Brimonidine tartrate ophthalmic solution 0.025%, Sterile balanced saline solution
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 6, 2026, 9:48 PM EDT